209 related articles for article (PubMed ID: 37110810)
21. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target.
Gao F; Liu T; Tuo M; Chi S
Neurosci Lett; 2021 Nov; 765():136247. PubMed ID: 34530113
[TBL] [Abstract][Full Text] [Related]
22. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
23. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System.
Fragale JE; James MH; Avila JA; Spaeth AM; Aurora RN; Langleben D; Aston-Jones G
Front Neurol Neurosci; 2021; 45():117-127. PubMed ID: 34052815
[TBL] [Abstract][Full Text] [Related]
24. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
[TBL] [Abstract][Full Text] [Related]
25. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
26. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
27. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
Transl Psychiatry; 2019 Sep; 9(1):216. PubMed ID: 31481683
[TBL] [Abstract][Full Text] [Related]
28. Orexin research: patent news from 2016.
Boss C; Roch C
Expert Opin Ther Pat; 2017 Oct; 27(10):1123-1133. PubMed ID: 28631980
[TBL] [Abstract][Full Text] [Related]
29. Orexin A in adolescents with anxiety disorders.
Akça ÖF; Uzun N; Kılınç İ
Int J Psychiatry Clin Pract; 2020 Jun; 24(2):127-134. PubMed ID: 31913740
[No Abstract] [Full Text] [Related]
30. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.
Staton CD; Yaeger JDW; Khalid D; Haroun F; Fernandez BS; Fernandez JS; Summers BK; Summers TR; Sathyanesan M; Newton SS; Summers CH
Neuropharmacology; 2018 Dec; 143():79-94. PubMed ID: 30240784
[TBL] [Abstract][Full Text] [Related]
31. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Futamura A; Suzuki R; Tamura Y; Kawamoto H; Ohmichi M; Hino N; Tokumaru Y; Kirinuki S; Hiyoshi T; Aoki T; Kambe D; Nozawa D
Bioorg Med Chem; 2020 Jul; 28(13):115489. PubMed ID: 32482533
[TBL] [Abstract][Full Text] [Related]
32. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
33. Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model.
Federici LM; Caliman IF; Molosh AI; Fitz SD; Truitt WA; Bonaventure P; Carpenter JS; Shekhar A; Johnson PL
Psychoneuroendocrinology; 2016 Mar; 65():127-37. PubMed ID: 26765933
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
Savitz A; Wajs E; Zhang Y; Xu H; Etropolski M; Thase ME; Drevets WC
Int J Neuropsychopharmacol; 2021 Dec; 24(12):965-976. PubMed ID: 34324636
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
36. Orexinergic modulation of serotonin neurons in the dorsal raphe of a diurnal rodent, Arvicanthis niloticus.
Adidharma W; Deats SP; Ikeno T; Lipton JW; Lonstein JS; Yan L
Horm Behav; 2019 Nov; 116():104584. PubMed ID: 31445011
[TBL] [Abstract][Full Text] [Related]
37. SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats.
Kordi Jaz E; Moghimi A; Fereidoni M; Asadi S; Shamsizadeh A; Roohbakhsh A
Fundam Clin Pharmacol; 2017 Apr; 31(2):201-207. PubMed ID: 27739093
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment.
Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S
Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404
[TBL] [Abstract][Full Text] [Related]
39. Intra-accumbal orexin-1 receptor inhibition prevents the anxiolytic-like effect of ethanol and leads to increases in orexin-A content and receptor expression.
Morales-Mulia M
Pharmacol Biochem Behav; 2019 Oct; 185():172761. PubMed ID: 31425712
[TBL] [Abstract][Full Text] [Related]
40. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).
Boss C; Roch C
Expert Opin Ther Pat; 2016; 26(3):409-15. PubMed ID: 26593218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
